Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 200-page biotech filing packed with clinical jargon isn’t how most investors want to spend the day. Lixte Biotechnology Holdings Inc.’s reports detail protein phosphatase science, LB-100 trial data, and dilution-sensitive financings that can be hard to track. If you have ever typed “Lixte Biotechnology Holdings SEC filings explained simply” or wondered how to locate a single table on R&D spend, you know the challenge.
Stock Titan solves it. Our AI reviews every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event the moment they hit EDGAR, then highlights what matters—cash runway, clinical milestones, licensing revenue, and risk factor changes. Need real-time alerts? “Lixte Biotechnology Holdings Form 4 insider transactions real-time” are surfaced within seconds so you can monitor executive stock transactions before the market reacts.
Explore the complete library:
- “Lixte Biotechnology Holdings quarterly earnings report 10-Q filing” with AI commentary on trial expenses and burn rate
- “Lixte Biotechnology Holdings annual report 10-K simplified” showing pipeline timelines and going-concern language
- “Lixte Biotechnology Holdings proxy statement executive compensation” connecting stock grants to development milestones
- “Lixte Biotechnology Holdings insider trading Form 4 transactions” plus historical charts
- “Lixte Biotechnology Holdings 8-K material events explained” for sudden trial updates or capital raises
Under the hood, our expert models translate technical oncology disclosures into clear, actionable insights. Track cash use, compare quarter-over-quarter pipeline progress, and understand how each filing affects valuation without wading through dense scientific prose. Understanding Lixte Biotechnology Holdings SEC documents with AI is now as straightforward as reading a headline.
Lixte Biotechnology Holdings, Inc. called its 2025 Annual Meeting to vote on three items: elect five directors, ratify Weinberg & Company, P.A. as auditor, and amend the 2020 Stock Incentive Plan to increase shares issuable by 2,750,000 to a total of 3,500,000 shares.
The virtual meeting is on December 8, 2025 at 1:00 p.m. ET. The record date is October 14, 2025, when 5,704,200 common shares were outstanding and entitled to vote. Director nominees are Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix and Guy Primus. The board recommends voting “FOR” all proposals.
As context, under the 2020 Plan, unexpired stock options for 694,309 shares were outstanding and 55,691 shares remained available as of September 30, 2025. The company reports a three‑year average net burn rate of 6.1%. For audit services, fees billed to Weinberg totaled $143,618 in 2024.
FAQ
What is the current stock price of Lixte Biotechnology Hldgs (LIXT)?
What is the market cap of Lixte Biotechnology Hldgs (LIXT)?
